The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

E. R. Gaynor, L. Vitek, L. Sticklin, S. P. Creekmore, M. E. Ferraro, J. X. Thomas, S. G. Fisher, R. I. Fisher

Research output: Contribution to journalArticlepeer-review

104 Scopus citations


In 1976, Morgan and colleagues first described the T-cell growth factor, interleukin-2, which is a glycoprotein with several in-vitro and in-vivo immunoregulatory effects. In addition to enhancing natural killer cell function, the incubation of peripheral blood lymphocytes with interleukin-2 results in the generation of lymphokine-activated killer cells. Lymphokine-activated killer cells can lyse fresh, autologous, or syngeneic tumor cells but show no lytic activity toward normal cells. The selective destruction of tumor cells thus theoretically provides the ideal cancer therapy: that is, one that destroys tumor cells while leaving normal host cells unharmed. Unfortunately, significant toxicity has limited the amount of interleukin-2 that can be safely administered to humans. Clearly, one of the most significant toxicities associated with interleukin-2 therapy is its effect on the cardiovascular system. Because of this predictable hemodynamic toxicity of interleukin-2 and because of its clinical importance, we studied the hemodynamic alterations occurring during interleukin-2 therapy in 13 patients.

Original languageEnglish (US)
Pages (from-to)953-958
Number of pages6
JournalAnnals of internal medicine
Issue number12
StatePublished - 1988

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells'. Together they form a unique fingerprint.

Cite this